ID: ALA358037

Max Phase: Preclinical

Molecular Formula: C20H26O8

Molecular Weight: 394.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(COc2cc(OC)c(OC)c(OC)c2)cc1OCC(O)CO

Standard InChI:  InChI=1S/C20H26O8/c1-23-16-6-5-13(7-17(16)28-12-14(22)10-21)11-27-15-8-18(24-2)20(26-4)19(9-15)25-3/h5-9,14,21-22H,10-12H2,1-4H3

Standard InChI Key:  MGYHEJDITQIJLQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 394.42

Molecular Weight (Monoisotopic): 394.1628

AlogP: 2.03

#Rotatable Bonds: 11

Polar Surface Area: 95.84

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.62

CX Basic pKa:

CX LogP: 1.43

CX LogD: 1.43

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.60

Np Likeness Score: 0.17

References

1. Lawrence NJ, Rennison D, Woo M, McGown AT, Hadfield JA..  (2001)  Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers.,  11  (1): [PMID:11140732] [10.1016/s0960-894x(00)00596-5]

2. Ducki S, Mackenzie G, Lawrence NJ, Snyder JP..  (2005)  Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.,  48  (2): [PMID:15658859] [10.1021/jm049444m]

Source

Source(1):

• Scientific Literature